Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 46 entries
Sorted by: Best Match Show Resources per page
Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression.

Cancers

Gong Y, Chippada-Venkata UD, Oh WK.
PMID: 24978435
Cancers (Basel). 2014 Jun 27;6(3):1298-327. doi: 10.3390/cancers6031298.

Matrix metalloproteinases (MMPs), a group of zinc-dependent endopeptidases involved in the degradation of the extracellular matrix, play an important role in tissue remodeling associated with various physiological processes such as morphogenesis, angiogenesis, and tissue repair, as well as pathological...

Cite
Gong Y, Chippada-Venkata UD, Oh WK. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel). 2014;6(3):1298-327doi: 10.3390/cancers6031298.
Gong, Y., Chippada-Venkata, U. D., & Oh, W. K. (2014). Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers, 6(3), 1298-327. https://doi.org/10.3390/cancers6031298
Gong, Yixuan, et al. "Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression." Cancers vol. 6,3 (2014): 1298-327. doi: https://doi.org/10.3390/cancers6031298
Gong Y, Chippada-Venkata UD, Oh WK. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel). 2014 Jun 27;6(3):1298-327. doi: 10.3390/cancers6031298. PMID: 24978435; PMCID: PMC4190542.
Copy Download .nbib Format: NLM
New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors.

The oncologist

Rothenberg ML, Nelson AR, Hande KR.
PMID: 10388115
Oncologist. 1998;3(4):271-274.

Matrix metalloproteinases (MMPs) are a family of enzymes involved in a number of normal cellular processes, such as regulation of endometrial growth and menstruation, and abnormal processes, such as tumor growth, invasion, and metastasis. There are now 18 distinct...

Cite
Rothenberg ML, Nelson AR, Hande KR. New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors. Oncologist. 1998;3(4):271-274
Rothenberg, M. L., Nelson, A. R., & Hande, K. R. (1998). New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors. The oncologist, 3(4), 271-274.
Rothenberg, et al. "New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors." The oncologist vol. 3,4 (1998): 271-274.
Rothenberg ML, Nelson AR, Hande KR. New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors. Oncologist. 1998;3(4):271-274. PMID: 10388115.
Copy Download .nbib Format: NLM
Matrix metalloproteinase inhibitors: past lessons and future prospects in breast cancer.

Breast (Edinburgh, Scotland)

Glasspool RM, Twelves CJ.
PMID: 14965609
Breast. 2001 Oct;10(5):368-78. doi: 10.1054/brst.2000.0254.

The matrix metalloproteinases (MMPs) play a central role in invasion and metastasis. However, despite striking activity in preclinical models, the clinical development of the matrix metalloproteinase inhibitors (MMPIs) has been difficult. The results of important phase III trials are...

Cite
Glasspool RM, Twelves CJ. Matrix metalloproteinase inhibitors: past lessons and future prospects in breast cancer. Breast. 2001;10(5):368-78doi: 10.1054/brst.2000.0254.
Glasspool, R. M., & Twelves, C. J. (2001). Matrix metalloproteinase inhibitors: past lessons and future prospects in breast cancer. Breast (Edinburgh, Scotland), 10(5), 368-78. https://doi.org/10.1054/brst.2000.0254
Glasspool, R M, and Twelves, C J. "Matrix metalloproteinase inhibitors: past lessons and future prospects in breast cancer." Breast (Edinburgh, Scotland) vol. 10,5 (2001): 368-78. doi: https://doi.org/10.1054/brst.2000.0254
Glasspool RM, Twelves CJ. Matrix metalloproteinase inhibitors: past lessons and future prospects in breast cancer. Breast. 2001 Oct;10(5):368-78. doi: 10.1054/brst.2000.0254. PMID: 14965609.
Copy Download .nbib Format: NLM
The design of selective non-substrate-based matrix metalloproteinase inhibitors.

Current opinion in drug discovery & development

Montana J, Baxter A.
PMID: 19649867
Curr Opin Drug Discov Devel. 2000 Jul;3(4):353-61.

A significant number of the matrix metalloproteinase (MMP) gene family of zinc-dependent enzymes have been implicated in a variety of diseases. This has fuelled considerable interest from the pharmaceutical industry in the identification and development of inhibitors of this...

Cite
Montana J, Baxter A. The design of selective non-substrate-based matrix metalloproteinase inhibitors. Curr Opin Drug Discov Devel. 2000;3(4):353-61
Montana, J., & Baxter, A. (2000). The design of selective non-substrate-based matrix metalloproteinase inhibitors. Current opinion in drug discovery & development, 3(4), 353-61.
Montana, J, and Baxter, A. "The design of selective non-substrate-based matrix metalloproteinase inhibitors." Current opinion in drug discovery & development vol. 3,4 (2000): 353-61.
Montana J, Baxter A. The design of selective non-substrate-based matrix metalloproteinase inhibitors. Curr Opin Drug Discov Devel. 2000 Jul;3(4):353-61. PMID: 19649867.
Copy Download .nbib Format: NLM
Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine.

Journal of oral microbiology

Gu Y, Walker C, Ryan ME, Payne JB, Golub LM.
PMID: 23071896
J Oral Microbiol. 2012;4. doi: 10.3402/jom.v4i0.19227. Epub 2012 Oct 12.

In 1983, it was first reported that tetracyclines (TCs) can modulate the host response, including (but not limited to) inhibition of pathologic matrix metalloproteinase (MMP) activity, and by mechanisms unrelated to the antibacterial properties of these drugs. Soon thereafter,...

Cite
Gu Y, Walker C, Ryan ME, et al. Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine. J Oral Microbiol. 2012;4doi: 10.3402/jom.v4i0.19227.
Gu, Y., Walker, C., Ryan, M. E., Payne, J. B., & Golub, L. M. (2012). Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine. Journal of oral microbiology, 4. https://doi.org/10.3402/jom.v4i0.19227
Gu, Ying, et al. "Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine." Journal of oral microbiology vol. 4 (2012). doi: https://doi.org/10.3402/jom.v4i0.19227
Gu Y, Walker C, Ryan ME, Payne JB, Golub LM. Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine. J Oral Microbiol. 2012;4. doi: 10.3402/jom.v4i0.19227. Epub 2012 Oct 12. PMID: 23071896; PMCID: PMC3471324.
Copy Download .nbib Format: NLM
Amino Acid derivatives as new zinc binding groups for the design of selective matrix metalloproteinase inhibitors.

Journal of amino acids

Giustiniano M, Tortorella P, Agamennone M, Di Pizio A, Rossello A, Nuti E, Gomez-Monterrey I, Novellino E, Campiglia P, Vernieri E, Sala M, Bertamino A, Carotenuto A.
PMID: 23555050
J Amino Acids. 2013;2013:178381. doi: 10.1155/2013/178381. Epub 2013 Mar 10.

A number of matrix metalloproteinases (MMPs) are important medicinal targets for conditions ranging from rheumatoid arthritis to cardiomyopathy, periodontal disease, liver cirrhosis, multiple sclerosis, and cancer invasion and metastasis, where they showed to have a dual role, inhibiting or...

Cite
Giustiniano M, Tortorella P, Agamennone M, et al. Amino Acid derivatives as new zinc binding groups for the design of selective matrix metalloproteinase inhibitors. J Amino Acids. 2013;2013:178381doi: 10.1155/2013/178381.
Giustiniano, M., Tortorella, P., Agamennone, M., Di Pizio, A., Rossello, A., Nuti, E., Gomez-Monterrey, I., Novellino, E., Campiglia, P., Vernieri, E., Sala, M., Bertamino, A., & Carotenuto, A. (2013). Amino Acid derivatives as new zinc binding groups for the design of selective matrix metalloproteinase inhibitors. Journal of amino acids, 2013178381. https://doi.org/10.1155/2013/178381
Giustiniano, Mariateresa, et al. "Amino Acid derivatives as new zinc binding groups for the design of selective matrix metalloproteinase inhibitors." Journal of amino acids vol. 2013 (2013): 178381. doi: https://doi.org/10.1155/2013/178381
Giustiniano M, Tortorella P, Agamennone M, Di Pizio A, Rossello A, Nuti E, Gomez-Monterrey I, Novellino E, Campiglia P, Vernieri E, Sala M, Bertamino A, Carotenuto A. Amino Acid derivatives as new zinc binding groups for the design of selective matrix metalloproteinase inhibitors. J Amino Acids. 2013;2013:178381. doi: 10.1155/2013/178381. Epub 2013 Mar 10. PMID: 23555050; PMCID: PMC3608355.
Copy Download .nbib Format: NLM
Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid.

EJNMMI radiopharmacy and chemistry

Hugenberg V, Behrends M, Wagner S, Hermann S, Schäfers M, Kolb HC, Szardenings K, Walsh JC, Gomez LF, Kopka K, Haufe G.
PMID: 30101186
EJNMMI Radiopharm Chem. 2018 Jul 27;3:10. doi: 10.1186/s41181-018-0045-0. eCollection 2018 Dec.

BACKGROUND: To study MMP activity in vivo in disease, several radiolabeled MMP inhibitors functioning as radiotracers have been evaluated by means of SPECT and PET. Unfortunately, most of them suffer from metabolic instability, mainly hepatobiliary clearance and insufficient target...

Cite
Hugenberg V, Behrends M, Wagner S, et al. Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid. EJNMMI Radiopharm Chem. 2018;3:10doi: 10.1186/s41181-018-0045-0.
Hugenberg, V., Behrends, M., Wagner, S., Hermann, S., Schäfers, M., Kolb, H. C., Szardenings, K., Walsh, J. C., Gomez, L. F., Kopka, K., & Haufe, G. (2018). Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid. EJNMMI radiopharmacy and chemistry, 310. https://doi.org/10.1186/s41181-018-0045-0
Hugenberg, Verena, et al. "Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid." EJNMMI radiopharmacy and chemistry vol. 3 (2018): 10. doi: https://doi.org/10.1186/s41181-018-0045-0
Hugenberg V, Behrends M, Wagner S, Hermann S, Schäfers M, Kolb HC, Szardenings K, Walsh JC, Gomez LF, Kopka K, Haufe G. Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid. EJNMMI Radiopharm Chem. 2018 Jul 27;3:10. doi: 10.1186/s41181-018-0045-0. eCollection 2018 Dec. PMID: 30101186; PMCID: PMC6063323.
Copy Download .nbib Format: NLM
Sulfur mustard research--strategies for the development of improved medical therapy.

Eplasty

Kehe K, Balszuweit F, Emmler J, Kreppel H, Jochum M, Thiermann H.
PMID: 18615149
Eplasty. 2008 Jun 10;8:e32.

OBJECTIVE: Sulfur mustard (SM) is a bifunctional alkylating substance being used as chemical warfare agent (vesicant). It is still regarded as a significant threat in chemical warfare and terrorism. Exposure to SM produces cutaneous blisters, respiratory and gastrointestinal tract...

Cite
Kehe K, Balszuweit F, Emmler J, et al. Sulfur mustard research--strategies for the development of improved medical therapy. Eplasty. 2008;8:e32
Kehe, K., Balszuweit, F., Emmler, J., Kreppel, H., Jochum, M., & Thiermann, H. (2008). Sulfur mustard research--strategies for the development of improved medical therapy. Eplasty, 8e32.
Kehe, Kai, et al. "Sulfur mustard research--strategies for the development of improved medical therapy." Eplasty vol. 8 (2008): e32.
Kehe K, Balszuweit F, Emmler J, Kreppel H, Jochum M, Thiermann H. Sulfur mustard research--strategies for the development of improved medical therapy. Eplasty. 2008 Jun 10;8:e32. PMID: 18615149; PMCID: PMC2431646.
Copy Download .nbib Format: NLM
Effects of topical intranasal doxycycline treatment in the rat allergic rhinitis model.

Clinical and experimental otorhinolaryngology

Avincsal MO, Ozbal S, Ikiz AO, Pekcetin C, Güneri EA.
PMID: 24917906
Clin Exp Otorhinolaryngol. 2014 Jun;7(2):106-11. doi: 10.3342/ceo.2014.7.2.106. Epub 2014 May 21.

OBJECTIVES: Allergic rhinitis (AR) is a chronic upper respiratory tract disease that inflames the mucous membranes of the nose and occurs when circulating inflammatory cells including eosinophils and basophils migrate to and accumulate in the inflammation area by passing...

Cite
Avincsal MO, Ozbal S, Ikiz AO, et al. Effects of topical intranasal doxycycline treatment in the rat allergic rhinitis model. Clin Exp Otorhinolaryngol. 2014;7(2):106-11doi: 10.3342/ceo.2014.7.2.106.
Avincsal, M. O., Ozbal, S., Ikiz, A. O., Pekcetin, C., & Güneri, E. A. (2014). Effects of topical intranasal doxycycline treatment in the rat allergic rhinitis model. Clinical and experimental otorhinolaryngology, 7(2), 106-11. https://doi.org/10.3342/ceo.2014.7.2.106
Avincsal, Mehmet Ozgür, et al. "Effects of topical intranasal doxycycline treatment in the rat allergic rhinitis model." Clinical and experimental otorhinolaryngology vol. 7,2 (2014): 106-11. doi: https://doi.org/10.3342/ceo.2014.7.2.106
Avincsal MO, Ozbal S, Ikiz AO, Pekcetin C, Güneri EA. Effects of topical intranasal doxycycline treatment in the rat allergic rhinitis model. Clin Exp Otorhinolaryngol. 2014 Jun;7(2):106-11. doi: 10.3342/ceo.2014.7.2.106. Epub 2014 May 21. PMID: 24917906; PMCID: PMC4050081.
Copy Download .nbib Format: NLM
New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

Biochemistry research international

Devy L, Dransfield DT.
PMID: 21152183
Biochem Res Int. 2011;2011:191670. doi: 10.1155/2011/191670. Epub 2010 Oct 28.

MMP intervention strategies have met with limited clinical success due to severe toxicities. In particular, treatment with broad-spectrum MMP-inhibitors (MMPIs) caused musculoskeletal pain and inflammation. Selectivity may be essential for realizing the clinical potential of MMPIs. Here we review...

Cite
Devy L, Dransfield DT. New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies. Biochem Res Int. 2010;2011:191670doi: 10.1155/2011/191670.
Devy, L., & Dransfield, D. T. (2011). New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies. Biochemistry research international, 2011191670. https://doi.org/10.1155/2011/191670
Devy, Laetitia, and Dransfield, Daniel T. "New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies." Biochemistry research international vol. 2011 (2011): 191670. doi: https://doi.org/10.1155/2011/191670
Devy L, Dransfield DT. New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies. Biochem Res Int. 2011;2011:191670. doi: 10.1155/2011/191670. Epub 2010 Oct 28. PMID: 21152183; PMCID: PMC2989751.
Copy Download .nbib Format: NLM
Tendinosis: pathophysiology and nonoperative treatment.

Sports health

Kaeding C, Best TM.
PMID: 23015885
Sports Health. 2009 Jul;1(4):284-92. doi: 10.1177/1941738109337778.

Tendinosis is a troublesome clinical entity affecting many active people. Its treatment remains a challenge to sports medicine clinicians. The etiopathophysiology of tendinosis has not been well delineated. The known pathophysiology and the recent advances in the understanding of...

Cite
Kaeding C, Best TM. Tendinosis: pathophysiology and nonoperative treatment. Sports Health. 2009;1(4):284-92doi: 10.1177/1941738109337778.
Kaeding, C., & Best, T. M. (2009). Tendinosis: pathophysiology and nonoperative treatment. Sports health, 1(4), 284-92. https://doi.org/10.1177/1941738109337778
Kaeding, Christopher, and Best, Thomas M. "Tendinosis: pathophysiology and nonoperative treatment." Sports health vol. 1,4 (2009): 284-92. doi: https://doi.org/10.1177/1941738109337778
Kaeding C, Best TM. Tendinosis: pathophysiology and nonoperative treatment. Sports Health. 2009 Jul;1(4):284-92. doi: 10.1177/1941738109337778. PMID: 23015885; PMCID: PMC3445129.
Copy Download .nbib Format: NLM
Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage.

Neurocritical care

Kearns KN, Ironside N, Park MS, Worrall BB, Southerland AM, Chen CJ, Ding D.
PMID: 34341912
Neurocrit Care. 2021 Dec;35(3):862-886. doi: 10.1007/s12028-021-01311-3. Epub 2021 Aug 02.

Patients who survive the initial ictus of spontaneous intracerebral hemorrhage (ICH) remain vulnerable to subsequent injury of the perilesional parenchyma by molecular and cellular responses to the hematoma. Secondary brain injury after ICH, which contributes to long-term functional impairment...

Cite
Kearns KN, Ironside N, Park MS, et al. Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage. Neurocrit Care. 2021;35(3):862-886doi: 10.1007/s12028-021-01311-3.
Kearns, K. N., Ironside, N., Park, M. S., Worrall, B. B., Southerland, A. M., Chen, C. J., & Ding, D. (2021). Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage. Neurocritical care, 35(3), 862-886. https://doi.org/10.1007/s12028-021-01311-3
Kearns, Kathryn N, et al. "Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage." Neurocritical care vol. 35,3 (2021): 862-886. doi: https://doi.org/10.1007/s12028-021-01311-3
Kearns KN, Ironside N, Park MS, Worrall BB, Southerland AM, Chen CJ, Ding D. Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage. Neurocrit Care. 2021 Dec;35(3):862-886. doi: 10.1007/s12028-021-01311-3. Epub 2021 Aug 02. PMID: 34341912.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 46 entries